Source: Tim--MRF
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
Tuesday, March 29, 2011
A call for patients that failed PLX-4032 Melanoma Jim Breitfeller
Genentech has just opened a study for people who have taken the Plexxikon/Roche/Genentech BRAF inhibitor, also known as PLX 4032. This study is a combination trial using PLX plus a MEK inhibitor. Some folks from this board have been in the BRAF/MEK trial being run by GSK, and this new trial is similar. One criteria, though, is that you must have taken the Plexxikon drug and have developed resistance to that drug. Currently three sites are open: Dr. Gajewski in Chicago, Dr. Ribas in UCLA, and Dr. Gonzalez in Denver. Four more sites will open soon. You can go to this link to find out information about melanoma relevant clinical trials, including this one: http://www.emergingmed.com/networks/MRF
Source: Tim--MRF
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
Source: Tim--MRF
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
Saturday, March 26, 2011
Profitable are the sick, for they shall be exploited..Melanoma..BMS ..Jim Breitfeller
Profitable are the sick, for they shall be exploited
I know many Melanoma Patients turned away by Bristol Myer Squibb.
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
I know many Melanoma Patients turned away by Bristol Myer Squibb.
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
Friday, March 25, 2011
F.D.A. Approves Drug to Treat Melanoma..Jim Breitfeller
The FDA just announced that they have approved Yervoy "ipi" for unresectable and metastatic melanoma. This is the first time a drug has been approved for melanoma in 13 years, so great news!
Here's the announcement:
FDA NEWS RELEASE
For Immediate Release: March 25, 2011
Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
FDA approves new treatment for a type of late-stage skin cancer
Melanoma patients lived longer with treatment
The U.S. Food and Drug Administration today approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer.
Melanoma is the leading cause of death from skin disease. An estimated 68,130 new cases of melanoma were diagnosed in the United States during 2010 and about 8,700 people died from the disease, according to the National Cancer Institute.
"Late-stage melanoma is devastating, with very few treatment options for patients, none of which previously prolonged a patient's life," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "Yervoy is the first therapy approved by the FDA to clearly demonstrate that patients with metastatic melanoma live longer by taking this treatment."
Yervoy is a monoclonal antibody that blocks a molecule known as cytotoxic T-lymphocyte antigen or CTLA-4. CTLA-4 may play a role in slowing down or turning off the body's immune system, affecting its ability to fight off cancerous cells. Yervoy may work by allowing the body's immune system to recognize, target, and attack cells in melanoma tumors. The drug is administered intravenously.
Yervoy's safety and effectiveness were established in a single international study of 676 patients with melanoma. All patients in the study had stopped responding to other FDA-approved or commonly used treatments for melanoma. In addition, participants had disease that had spread or that could not be surgically removed.
The study was designed to measure overall survival, the length of time from when this treatment started until a patient's death. The randomly assigned patients received Yervoy plus an experimental tumor vaccine called gp100, Yervoy alone, or the vaccine alone.
Those who received the combination of Yervoy plus the vaccine or Yervoy alone lived an average of about 10 months, while those who received only the experimental vaccine lived an average of 6.5 months.
Common side effects that can result from autoimmune reactions associated with Yervoy use include fatigue, diarrhea, skin rash, endocrine deficiencies (gland or hormone), and inflammation of the intestines (colitis). Severe to fatal autoimmune reactions were seen in 12.9 percent of patients treated with Yervoy.When severe side effects occurred, Yervoy was stopped and corticosteroid treatment was started. Not all patients responded to this treatment. Patients who did respond in some cases did not see any improvement for several weeks.
Due to the unusual and severe side effects associated with Yervoy, the therapy is being approved with a Risk Evaluation and Mitigation Strategy to inform health care professionals about these serious risks. A medication guide will also be provided to patients to inform them about the therapy's potential side effects.
Yervoy is marketed by New York City-based Bristol-Myers Squibb.
For more information:
FDA: Office of Oncology Drug Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm
FDA: Approved Risk Evaluation and Mitigation Strategies (REMS)
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm
FDA: Approved Drugs: Questions and Answers
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm
NCI: Melanoma
http://www.cancer.gov/cancertopics/types/melanoma
CDC: Skin Cancer
http://www.cdc.gov/cancer/skin/
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
Here's the announcement:
FDA NEWS RELEASE
For Immediate Release: March 25, 2011
Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA
FDA approves new treatment for a type of late-stage skin cancer
Melanoma patients lived longer with treatment
The U.S. Food and Drug Administration today approved Yervoy (ipilimumab) to treat patients with late-stage (metastatic) melanoma, the most dangerous type of skin cancer.
Melanoma is the leading cause of death from skin disease. An estimated 68,130 new cases of melanoma were diagnosed in the United States during 2010 and about 8,700 people died from the disease, according to the National Cancer Institute.
"Late-stage melanoma is devastating, with very few treatment options for patients, none of which previously prolonged a patient's life," said Richard Pazdur, M.D., director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "Yervoy is the first therapy approved by the FDA to clearly demonstrate that patients with metastatic melanoma live longer by taking this treatment."
Yervoy is a monoclonal antibody that blocks a molecule known as cytotoxic T-lymphocyte antigen or CTLA-4. CTLA-4 may play a role in slowing down or turning off the body's immune system, affecting its ability to fight off cancerous cells. Yervoy may work by allowing the body's immune system to recognize, target, and attack cells in melanoma tumors. The drug is administered intravenously.
Yervoy's safety and effectiveness were established in a single international study of 676 patients with melanoma. All patients in the study had stopped responding to other FDA-approved or commonly used treatments for melanoma. In addition, participants had disease that had spread or that could not be surgically removed.
The study was designed to measure overall survival, the length of time from when this treatment started until a patient's death. The randomly assigned patients received Yervoy plus an experimental tumor vaccine called gp100, Yervoy alone, or the vaccine alone.
Those who received the combination of Yervoy plus the vaccine or Yervoy alone lived an average of about 10 months, while those who received only the experimental vaccine lived an average of 6.5 months.
Common side effects that can result from autoimmune reactions associated with Yervoy use include fatigue, diarrhea, skin rash, endocrine deficiencies (gland or hormone), and inflammation of the intestines (colitis). Severe to fatal autoimmune reactions were seen in 12.9 percent of patients treated with Yervoy.When severe side effects occurred, Yervoy was stopped and corticosteroid treatment was started. Not all patients responded to this treatment. Patients who did respond in some cases did not see any improvement for several weeks.
Due to the unusual and severe side effects associated with Yervoy, the therapy is being approved with a Risk Evaluation and Mitigation Strategy to inform health care professionals about these serious risks. A medication guide will also be provided to patients to inform them about the therapy's potential side effects.
Yervoy is marketed by New York City-based Bristol-Myers Squibb.
For more information:
FDA: Office of Oncology Drug Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm
FDA: Approved Risk Evaluation and Mitigation Strategies (REMS)
http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm
FDA: Approved Drugs: Questions and Answers
http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm054420.htm
NCI: Melanoma
http://www.cancer.gov/cancertopics/types/melanoma
CDC: Skin Cancer
http://www.cdc.gov/cancer/skin/
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
Thursday, March 24, 2011
Late-Breaking Abstracts..Melanoma ..Jim Breitfeller
Late-Breaking Abstracts
2010 Annual Meeting; Washington, D.C., October 2-4, 2010 3
International Society for Biological Therapy of Cancer (iSBTc; now known as the Society for Immunotherapy of Cancer; SITC)
-162-
USING TIMING TO SYNCHRONISE IMMUNOTHERAPY THROUGH
MICROMANIPULATION OF THE UNDERLYING TUMOR IMMUNE RESPONSE:
FROM COLEY TO ROSENBERG, LOTZE, ALLISON, WOLCHOK AND BEYOND!
Brendon J. Coventry1, Martin L. Ashdown2, Svetomir N. Markovic3
1Surgery and Immunology, University of Adelaide, Adelaide, SA, Australia
2Medicine, University of Melbourne, Melbourne, VIC, Australia
3Medical Oncology, Mayo Clinic, Rochester, MN
Introduction: Immunotherapy studies in advanced cancers appear to show that the immune
response can be driven in either an ‘effector’ or ‘regulatory’ direction or a ‘mixture’ of these,
leading to the heterogeneous clinical responses (CR, PR, PD) seen. Using CRP as a marker, we
have shown that a repeating cyclical, dependent, sequential, orchestrated, homeostatic
physiologic process appears to be occurring in most, if not all, cancer patients, most likely as a
result of chronic antigenic stimulation. The correct timing of immunotherapy or chemotherapy
with this ‘immune cycle’ appears to be associated with better cancer control and improved
clinical outcomes.
We are concerned that the timing of therapy with respect to the underlying tumor immune
response fluctuations is the principal determinant of efficacy in cancer treatment. The
observations and model may also extend to other chronic inflammatory states to determine
therapeutic efficacy.
Methods: Using serial CRP measurements in late-stage cancer patients, we have recently been
able to expose sequential and time dependent oscillations in the inflammatory/ immune response
that may represent a homeostatic, repeating or cyclical process of tumour immune
responsiveness then tolerance. The periodicity of these cycles appears to be reproducible at
approximately 6-7 days.
By serially measuring CRP around the time of vaccination or chemotherapy, the position on the
underlying immune curve can be established. Timing with respect to this cycle appears to be
critical to modulating the immune system with each intervention, and pivotal to the clinical
efficacy of therapy (1,2).
Results: Using these methods, we have been able to correlate the timing of vaccination/
chemotherapy with the induction of clinical responses. Induction of complete responses, stable
disease, slowed growth even with persistent metastatic disease, appears possible using these
principles, thereby improving overall survival.
Conclusions: The historical ‘random successes’ seen with vaccines, cytokines and receptor
directed monoclonal antibodies may be due to their fortuitous accidental interference with the
underlying persistent, homeostatically regulated tumor immune kinetics by their ‘random’
untimed administration. By accurately and appropriately synchronizing therapy to each patient’s
immune system’s periodic oscillations - immune cycle - we predict that the current low random
immunotherapy successes seen to date, can be made more predictable by accurately timing
therapy better, and will achieve greater clinical efficacy.
Where have you heard the key to an immune response is dose and timming.
Right Here
Melanoma and the Magic Bullet
The Research paper called Melanoma and the Magic Bullet
The Research paper called The Making of an Immune Response by Combinatorial Therapy Using Anti-CTLA-4 Blockade and Interleukin-2
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
2010 Annual Meeting; Washington, D.C., October 2-4, 2010 3
International Society for Biological Therapy of Cancer (iSBTc; now known as the Society for Immunotherapy of Cancer; SITC)
-162-
USING TIMING TO SYNCHRONISE IMMUNOTHERAPY THROUGH
MICROMANIPULATION OF THE UNDERLYING TUMOR IMMUNE RESPONSE:
FROM COLEY TO ROSENBERG, LOTZE, ALLISON, WOLCHOK AND BEYOND!
Brendon J. Coventry1, Martin L. Ashdown2, Svetomir N. Markovic3
1Surgery and Immunology, University of Adelaide, Adelaide, SA, Australia
2Medicine, University of Melbourne, Melbourne, VIC, Australia
3Medical Oncology, Mayo Clinic, Rochester, MN
Introduction: Immunotherapy studies in advanced cancers appear to show that the immune
response can be driven in either an ‘effector’ or ‘regulatory’ direction or a ‘mixture’ of these,
leading to the heterogeneous clinical responses (CR, PR, PD) seen. Using CRP as a marker, we
have shown that a repeating cyclical, dependent, sequential, orchestrated, homeostatic
physiologic process appears to be occurring in most, if not all, cancer patients, most likely as a
result of chronic antigenic stimulation. The correct timing of immunotherapy or chemotherapy
with this ‘immune cycle’ appears to be associated with better cancer control and improved
clinical outcomes.
We are concerned that the timing of therapy with respect to the underlying tumor immune
response fluctuations is the principal determinant of efficacy in cancer treatment. The
observations and model may also extend to other chronic inflammatory states to determine
therapeutic efficacy.
Methods: Using serial CRP measurements in late-stage cancer patients, we have recently been
able to expose sequential and time dependent oscillations in the inflammatory/ immune response
that may represent a homeostatic, repeating or cyclical process of tumour immune
responsiveness then tolerance. The periodicity of these cycles appears to be reproducible at
approximately 6-7 days.
By serially measuring CRP around the time of vaccination or chemotherapy, the position on the
underlying immune curve can be established. Timing with respect to this cycle appears to be
critical to modulating the immune system with each intervention, and pivotal to the clinical
efficacy of therapy (1,2).
Results: Using these methods, we have been able to correlate the timing of vaccination/
chemotherapy with the induction of clinical responses. Induction of complete responses, stable
disease, slowed growth even with persistent metastatic disease, appears possible using these
principles, thereby improving overall survival.
Conclusions: The historical ‘random successes’ seen with vaccines, cytokines and receptor
directed monoclonal antibodies may be due to their fortuitous accidental interference with the
underlying persistent, homeostatically regulated tumor immune kinetics by their ‘random’
untimed administration. By accurately and appropriately synchronizing therapy to each patient’s
immune system’s periodic oscillations - immune cycle - we predict that the current low random
immunotherapy successes seen to date, can be made more predictable by accurately timing
therapy better, and will achieve greater clinical efficacy.
Where have you heard the key to an immune response is dose and timming.
Right Here
Melanoma and the Magic Bullet
The Research paper called Melanoma and the Magic Bullet
The Research paper called The Making of an Immune Response by Combinatorial Therapy Using Anti-CTLA-4 Blockade and Interleukin-2
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
Tuesday, March 22, 2011
Bristol-Myers Awaits Approval for Drug's New Cancer Attack
With This FDA Approval, This is the begining of the end cancer as we know it. Ipilimumab will revolutionize Cancer therapy along with Anti-PD-1 and HD IL-2.
Bristol-Myers Awaits Approval for Drug's New Cancer Attack
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
Bristol-Myers Awaits Approval for Drug's New Cancer Attack
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
Thursday, March 17, 2011
Sounding the Danger Signal through chemotherapy to Cause Cancer Cell Death..Melanoma ..Jim Breitfeller
Sounding the Danger Signal through chemotherapy to Cause Cancer Cell Death
“Schedule and Dose for Combination Therapy,”
2011 Scientific Colloquium of the Cancer Immunotherapy Consortium
Thursday, March 17, 2011 7:00 AM - Saturday, March 19, 2011 1:30 PM
Eastern Time
Dr. Hy Levitsky is introducing Dr. Laurence Zitvogel from Institut Gustave Roussy, a leader in cell biology in cancer.
New Speaker: Laurence Zitvogel, Ph.D.
Institut GustaveRoussy, Villejuif, France
"Dr. Zitvogel graduated in medical oncology from the School of Medicine of the University of Paris in 1992. She started her scientific career when she was at the University of Pittsburgh in Michael Lotze’s laboratory. She became research director at Institut National de la Santé et Recherche Médicale in a laboratory located at Institut Gustave Roussy, a large cancer center in Villejuif, France, and the head of the Center for Clinical Investigations for vaccine developments at Villejuif. Dr. Zitvogel has been actively contributing to the field of cancer immunology and immunotherapy, bringing together basic and translational research, including the design of cancer therapies through combined animal studies and phase I patient trials. Her expertise is mainly dendritic cell and innate effector biology and relevance during tumor development, as well as exosome-based vaccine designs."
Zitvogel: chemotherapy may work because cancer cell death is immunogenic and triggers anti-cancer immunity
Zitvogel: Chemo causes cancer to express "eat me" or "come and get me" signals to the immune system. Nice way to phrase it!
Jimmy B: See Graph Below
Autophagy Defintion: The process of self-digestion by a cell through the action of enzymes originating within the same cell.
Zitvogel: "autophagy" is important to death of cancer cells. It breaks down in cancer growth. Chemo re-starts the autophagy process.
Zitvogel: some types of chemo are better at inducing immunogenic cell death than others. Cisplatin and taxols aren't strong in this.
Zitvogel: new tests can show how a drug falls short in triggering immunogenic cancer death -- and how to compensate for that.
Zitvogel: Giving thapsigarin can improve cisplatin's ability to trigger immunogenic cancer cell death.
Jimmy B: Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis
Zitvogel: "drug repositioning" is the process of combining drugs to compensate for where one falls short in immunogenic cell death.
Zitvogel: combining immunogenic chemotherapies with immunomodulators or other immunotherapy is a very promising strategy.
Source: Cancer Research on Twitter
http://twitter.com/#!/search?q=%23cic11
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
“Schedule and Dose for Combination Therapy,”
2011 Scientific Colloquium of the Cancer Immunotherapy Consortium
Thursday, March 17, 2011 7:00 AM - Saturday, March 19, 2011 1:30 PM
Eastern Time
Dr. Hy Levitsky is introducing Dr. Laurence Zitvogel from Institut Gustave Roussy, a leader in cell biology in cancer.
New Speaker: Laurence Zitvogel, Ph.D.
Institut GustaveRoussy, Villejuif, France
"Dr. Zitvogel graduated in medical oncology from the School of Medicine of the University of Paris in 1992. She started her scientific career when she was at the University of Pittsburgh in Michael Lotze’s laboratory. She became research director at Institut National de la Santé et Recherche Médicale in a laboratory located at Institut Gustave Roussy, a large cancer center in Villejuif, France, and the head of the Center for Clinical Investigations for vaccine developments at Villejuif. Dr. Zitvogel has been actively contributing to the field of cancer immunology and immunotherapy, bringing together basic and translational research, including the design of cancer therapies through combined animal studies and phase I patient trials. Her expertise is mainly dendritic cell and innate effector biology and relevance during tumor development, as well as exosome-based vaccine designs."
Zitvogel: chemotherapy may work because cancer cell death is immunogenic and triggers anti-cancer immunity
Zitvogel: Chemo causes cancer to express "eat me" or "come and get me" signals to the immune system. Nice way to phrase it!
Jimmy B: See Graph Below
Autophagy Defintion: The process of self-digestion by a cell through the action of enzymes originating within the same cell.
Zitvogel: "autophagy" is important to death of cancer cells. It breaks down in cancer growth. Chemo re-starts the autophagy process.
Zitvogel: some types of chemo are better at inducing immunogenic cell death than others. Cisplatin and taxols aren't strong in this.
Zitvogel: new tests can show how a drug falls short in triggering immunogenic cancer death -- and how to compensate for that.
Zitvogel: Giving thapsigarin can improve cisplatin's ability to trigger immunogenic cancer cell death.
Jimmy B: Thapsigargin sensitizes human melanoma cells to TRAIL-induced apoptosis
Zitvogel: "drug repositioning" is the process of combining drugs to compensate for where one falls short in immunogenic cell death.
Zitvogel: combining immunogenic chemotherapies with immunomodulators or other immunotherapy is a very promising strategy.
Source: Cancer Research on Twitter
http://twitter.com/#!/search?q=%23cic11
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
“Schedule and Dose for Combination Therapy,” Melanoma.. 2011 Scientific Colloquium of the Cancer Immunotherapy
“Schedule and Dose for Combination Therapy,”
2011 Scientific Colloquium of the Cancer Immunotherapy Consortium
• Thursday, March 17, 2011 7:00 AM - Saturday, March 19, 2011 1:30 PM
Eastern Time
First Speaker: Dr. Rafi Ahmed
Director of the Emory Vaccine Center
"As a basic immunologist, EVC Director Dr. Rafi Ahmed studies immunological memory – the ability of the immune system to “remember” a particular antigen and respond accordingly. Dr. Ahmed and his colleagues have made significant discoveries about how immune memory cells are created and how long they survive; understanding these mechanisms is crucial to the development of vaccines for HIV and other infectious agents. In addition to contributing vitally to vaccine science, Dr. Ahmed’s findings are being applied to research into therapies for the treatment of cancer and the prevention of organ rejection."
Dr. Rafi Ahmed is now being introduced by Johannes Vieweg, & highlighting his work on immunological memory
Dr. Ahmed is sharing how lessons from immune memory development in chronic viral infection can inform cancer immunotherapy field
Ahmed: wait 30-60 days to boost in vaccination produces better immune responses for many types of viral vaccines. Same for cancer?JimmyB :Why 30 to 60 days? Because this is the time factor that it takes for the CD4+ and CD8+ T-cells to grow and differentiate into effector T-cells. (See Graph)
Fig-1
Dr. Rafi Ahmed is now being introduced by Johannes Vieweg, & highlighting his work on immunological memory Dr. Ahmed is sharing how lessons from immune memory development in chronic viral infection can inform cancer immunotherapy field Ahmed: wait 30-60 days to boost in vaccination produces better immune responses for many types of viral vaccines. Same for cancer?
Fig-2
Ahmed: Synergy we've seen combining PD-1 with IL-2 (negative + positive signal) in viral infection therapy have been astonishing.
Jimmy B:Imagine if you combine CTLA-4 + PD-1 and IL-2. The Holy Grail of Immuno therapy I believe.Ahmed raises point that mTOR inhibition may enhance vaccine-induced memory CD8 T-cells. Role for combining with cancer vaccines?
Much audience Q&A for Dr. Ahmed - when see exhaustion clinically, is it inhibition, effect of dose of IL-2, and role of autophagy?
Source: Cancer Research on Twitter
http://twitter.com/#!/search?q=%23cic11
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
2011 Scientific Colloquium of the Cancer Immunotherapy Consortium
• Thursday, March 17, 2011 7:00 AM - Saturday, March 19, 2011 1:30 PM
Eastern Time
First Speaker: Dr. Rafi Ahmed
Director of the Emory Vaccine Center
"As a basic immunologist, EVC Director Dr. Rafi Ahmed studies immunological memory – the ability of the immune system to “remember” a particular antigen and respond accordingly. Dr. Ahmed and his colleagues have made significant discoveries about how immune memory cells are created and how long they survive; understanding these mechanisms is crucial to the development of vaccines for HIV and other infectious agents. In addition to contributing vitally to vaccine science, Dr. Ahmed’s findings are being applied to research into therapies for the treatment of cancer and the prevention of organ rejection."
Dr. Rafi Ahmed is now being introduced by Johannes Vieweg, & highlighting his work on immunological memory
Dr. Ahmed is sharing how lessons from immune memory development in chronic viral infection can inform cancer immunotherapy field
Ahmed: wait 30-60 days to boost in vaccination produces better immune responses for many types of viral vaccines. Same for cancer?JimmyB :Why 30 to 60 days? Because this is the time factor that it takes for the CD4+ and CD8+ T-cells to grow and differentiate into effector T-cells. (See Graph)
Fig-1
Dr. Rafi Ahmed is now being introduced by Johannes Vieweg, & highlighting his work on immunological memory Dr. Ahmed is sharing how lessons from immune memory development in chronic viral infection can inform cancer immunotherapy field Ahmed: wait 30-60 days to boost in vaccination produces better immune responses for many types of viral vaccines. Same for cancer?
Fig-2
Ahmed: Synergy we've seen combining PD-1 with IL-2 (negative + positive signal) in viral infection therapy have been astonishing.
Jimmy B:Imagine if you combine CTLA-4 + PD-1 and IL-2. The Holy Grail of Immuno therapy I believe.Ahmed raises point that mTOR inhibition may enhance vaccine-induced memory CD8 T-cells. Role for combining with cancer vaccines?
Much audience Q&A for Dr. Ahmed - when see exhaustion clinically, is it inhibition, effect of dose of IL-2, and role of autophagy?
Source: Cancer Research on Twitter
http://twitter.com/#!/search?q=%23cic11
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
Friday, March 4, 2011
Interviews with Laurie and Bob from Melanoma ROADTRIP..Jim Breitfeller
Interviews with Laurie and Bob from Melanoma ROADTRIP
CP:boblawrencesjourney
boblawrencesjourney
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
CP:boblawrencesjourney
boblawrencesjourney
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
Tuesday, March 1, 2011
Breakthrough Drugs Target Deadly Cancer - Boston News Story - WCVB Boston
Combination Therapy BRAF + MEK
When it works, it works quite well.
Breakthrough Drugs Target Deadly Cancer - Boston News Story - WCVB Boston
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B
When it works, it works quite well.
Breakthrough Drugs Target Deadly Cancer - Boston News Story - WCVB Boston
“It is not the strongest of the species that survives, nor the most intelligent, but the one most responsive to change.”
~Charles Darwin~
Take Care,
Jimmy B